<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17385" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alopecia Areata</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lepe</surname>
            <given-names>Kenia</given-names>
          </name>
          <aff>Universidad de Guadalajara</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Syed</surname>
            <given-names>Hasnain A.</given-names>
          </name>
          <aff>Sheikh Zayed Hospital, Lahore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kenia Lepe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hasnain Syed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17385.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Alopecia areata is a chronic, immune-mediated autoimmune disorder that affects hair follicles, nails, and, occasionally, the retinal pigment epithelium. This condition targets the anagen hair follicles of individuals and leads to hair loss without permanent damage to the follicles.&#x000a0;The classic presentation of alopecia areata involves isolated, smooth, sudden, nonscarring, and patchy hair loss on the scalp or any area with hair growth.&#x000a0;This condition arises from an autoimmune disruption in the normal hair cycle, resulting in the loss of immune privilege in the hair follicles.</p>
        <p>Although many individuals experience spontaneous hair regrowth within 1 year, alopecia areata is a chronic condition characterized by recurring episodes of hair loss that require both psychological support and medical treatment. Various treatment options, such as corticosteroids, immunotherapy, Janus kinase (JAK) inhibitors, and topical solutions, are available to help manage the extent and duration of hair loss.&#x000a0;This activity helps clinicians acquire proficiency in selecting and using diverse treatment modalities for patients with alopecia areata. This activity also provides&#x000a0;pertinent knowledge to interprofessional healthcare teams to foster improved clinician-patient interactions by emphasizing mutual collaboration and holistic management. This approach leads to well-informed treatment decisions, enhanced patient outcomes, and improved quality of life for individuals with alopecia areata.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical manifestations and characteristic features of alopecia areata for accurate diagnosis.</p></list-item><list-item><p>Screen patients for signs and symptoms indicative of alopecia areata during routine examinations.</p></list-item><list-item><p>Implement evidence-based treatment strategies based on the severity and extent of hair loss in patients with alopecia areata.</p></list-item><list-item><p>Collaborate with interprofessional healthcare providers to coordinate care and provide holistic support to patients with alopecia areata by addressing both physical and psychosocial needs.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17385&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17385">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17385.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Alopecia areata is a chronic, immune-mediated autoimmune disorder that affects hair follicles, nails, and, occasionally, the retinal pigment epithelium.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref> This condition targets the anagen hair follicles of individuals and leads to hair loss without permanent damage to the follicles.&#x000a0;Alopecia areata&#x000a0;arises from an autoimmune disruption in the normal hair cycle, resulting in the loss of immune privilege in the hair follicles.</p>
        <p>Alopecia areata usually presents as localized patches of hair loss on the scalp, which develop over a few weeks (see&#x000a0;<bold>Image.&#x000a0;</bold>Alopecia Areata).&#x000a0;The classic presentation of alopecia areata involves isolated, smooth, sudden, nonscarring, and patchy hair loss on the scalp or any area with hair growth.<xref ref-type="bibr" rid="article-17385.r2">[2]</xref> Although many individuals experience spontaneous hair regrowth within 1 year, alopecia areata is a chronic condition characterized by recurring episodes of hair loss&#x000a0;that require both psychological support and medical treatment.&#x000a0;Various treatment options, such as corticosteroids, immunotherapy, Janus kinase (JAK) inhibitors, and topical solutions, are available to help manage the extent and duration of hair loss.&#x000a0;</p>
      </sec>
      <sec id="article-17385.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The hair cycle consists of 3 phases&#x02014;anagen, catagen, and telogen. During the anagen phase, active hair growth occurs, while the catagen phase involves the keratinization of the proximal end of the hair shaft. Subsequently, the hair follicle sheds and the remaining proximal end undergoes apoptosis. Telogen signifies the interval between the regression of the old follicle and the onset of the next anagen phase.</p>
        <p>During the anagen phase, 6 stages of hair growth occur, with stage VI representing a fully formed anagen follicle. However, in individuals with alopecia areata, the hair follicles become arrested in stage III or IV, prematurely reverting to the catagen or telogen phase and leading to abrupt hair loss and hair regrowth deficiency.</p>
      </sec>
      <sec id="article-17385.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The lifetime risk of developing alopecia areata in the general population is estimated&#x000a0;at 2%, with a prevalence of approximately 1 in 1000.<xref ref-type="bibr" rid="article-17385.r3">[3]</xref><xref ref-type="bibr" rid="article-17385.r4">[4]</xref>&#x000a0;Although data indicate no demonstrable sex predilection, alopecia areata occurs more often among Asian, Black, and Hispanic patients. Alopecia areata affects children and adults, and the incidence rises steadily with age. The mean age at onset is 32 for males and 36 for females.<xref ref-type="bibr" rid="article-17385.r5">[5]</xref>&#x000a0;</p>
        <p>Studies reveal that dermatologic and systemic conditions associated with alopecia areata include vitiligo, lupus erythematosus, psoriasis, atopic dermatitis, thyroid disease, and allergic rhinitis.<xref ref-type="bibr" rid="article-17385.r6">[6]</xref></p>
        <p>Patients with&#x000a0;Down syndrome (trisomy 21, MIM #190685) and polyglandular autoimmune syndrome type 1 (MIM #240300) have an increased risk of developing alopecia areata.<xref ref-type="bibr" rid="article-17385.r7">[7]</xref><xref ref-type="bibr" rid="article-17385.r8">[8]</xref><xref ref-type="bibr" rid="article-17385.r9">[9]</xref></p>
      </sec>
      <sec id="article-17385.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Specific critical body organs, including the eyes, central nervous system, testicles, fetus, and placenta, exhibit immune privilege, which is the ability to endure exposure to antigens without eliciting an inflammatory immune response. The loss of immune privilege within hair follicles and the subsequent immune dysregulation are central to the development of alopecia areata.<xref ref-type="bibr" rid="article-17385.r3">[3]</xref><xref ref-type="bibr" rid="article-17385.r4">[4]</xref></p>
        <p>Current evidence suggests that the cause of the condition is autoimmune, with a significant genetic contribution, further influenced by unknown environmental factors. Reported triggers include emotional or physical stress, vaccinations, viral infections, and medications.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref>&#x000a0;These triggers initiate the loss of immune privilege by inhibiting the production of 2 anti-inflammatory cytokines&#x02014;transforming growth factor-&#x003b2; (TGF-&#x003b2;) and &#x003b1;-melanocyte&#x02013;stimulating hormone (&#x003b1;-MSH). In addition, they stimulate the expression of major histocompatibility complex class&#x000a0;I (MHC-I) polypeptide-related sequence A (MICA) on hair follicles. Subsequently, natural killer (NK) cells become activated, leading to the secretion of interferon-&#x003b3; (IFN-&#x003b3;) and interleukin-15 (IL-15).</p>
        <p>IFN-&#x003b3; stimulates the expression of MHC-I proteins on hair follicle cells, revealing previously hidden antigens to T cells. Notably, IL-15 inhibits regulatory T cells. IFN-&#x003b3; and IL-15 activate target immune cells via the JAK signal transducer and activator of the transcription (JAK-STAT) signaling pathway. As a result, inflammatory cells target the hair follicle matrix epithelium undergoing early cortical differentiation or anagen hair follicles, prematurely pushing them into the catagen or telogen phase.</p>
      </sec>
      <sec id="article-17385.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The histopathological observations in areas of acute active hair loss reveal a distinctive "bee-swarm pattern" characterized by dense lymphocytic infiltrates surrounding the bulbar region of anagen hair follicles (see <bold>Image.</bold>&#x000a0;Alopecia Areata Biopsy).<xref ref-type="bibr" rid="article-17385.r1">[1]</xref>&#x000a0;This lymphocytic infiltrate comprises CD8+ T cells within the follicular epithelium and CD4+ T cells around the hair follicles.<xref ref-type="bibr" rid="article-17385.r10">[10]</xref> Biopsies from regions affected by chronic alopecia reveal follicular miniaturization.&#x000a0;</p>
      </sec>
      <sec id="article-17385.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Alopecia areata usually presents as localized patches of hair loss on the scalp that emerge over a few weeks. However, this condition can also affect other areas, such as the beard, eyebrows, eyelashes, and extremities (see <bold>Image.&#x000a0;</bold>Alopecia Areata Hair Loss). During active disease, exclamation-mark hairs, characterized by a narrower proximal end than the distal end, are commonly observed at the periphery of lesions and are a pathognomonic finding in patients with alopecia areata.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref>&#x000a0;In a minority of cases, patients may progress to total hair loss on the scalp, known as alopecia areata totalis. Furthermore, some individuals may experience complete hair loss across the entire body, termed alopecia universalis.</p>
        <p>The various patterns of alopecia areata are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ophiasis pattern:&#x000a0;Hair loss affecting the occipital region.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sisaipho (or ophiasis inversus) pattern:&#x000a0;Hair loss involving the frontal, temporal, and parietal scalp but spares the occipital region.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse pattern:&#x000a0;Rapidly progressive and diffuse hair loss followed by regrowth within several months.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>A subset of patients may experience total hair loss on the scalp, known as alopecia totalis, or total hair loss across the entire body, including the eyelashes and eyebrows, termed alopecia universalis. For additional information regarding the diagnosis and management of alopecia totalis and alopecia universalis, please refer to StatPearls' companion topic, "Totalis Alopecia"&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK563225/#:~:text=Alopecia%20totalis%20is%20a%20chronic,treated%20early%20in%20its%20course.">https://www.ncbi.nlm.nih.gov/books/</ext-link>.</p>
        <p>Approximately 10% to 15% of patients with alopecia areata experience nail involvement, characterized by fine nail pitting, trachyonychia, onychorrhexis, red spotting on the lunulae, onycholysis, and onychomadesis (see <bold>Image.</bold>&#x000a0;Alopecia Areata Dystrophic Nails). White hair is often spared, initially giving patients the appearance of rapid greying. In addition, individuals with alopecia areata also have an elevated risk of developing conditions such as retinal detachment, retinal vein occlusion, and retinopathy.<xref ref-type="bibr" rid="article-17385.r11">[11]</xref></p>
      </sec>
      <sec id="article-17385.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Alopecia areata is typically diagnosed clinically, relying on the patient's medical history and physical examination. Rapidly developing individual patches of alopecia on the skin, often accompanied by minimal erythema, should raise clinical suspicion. Dermoscopy serves as a valuable complementary diagnostic tool in confirming the diagnosis.<xref ref-type="bibr" rid="article-17385.r12">[12]</xref><xref ref-type="bibr" rid="article-17385.r13">[13]</xref></p>
        <p>Broken hairs, yellow dots, black dots, exclamation point hairs, and short vellus hairs indicate early regrowth.<xref ref-type="bibr" rid="article-17385.r14">[14]</xref>&#x000a0;The absence of hair follicles indicates cicatricial or scarring alopecia. Conducting a hair pull test can confirm active hair loss. Additionally, examination of the nails may reveal findings that support the diagnosis.</p>
        <p>A skin biopsy from the periphery of an active hair loss patch may be beneficial if the diagnosis remains uncertain.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref>&#x000a0;Although alopecia areata is associated with other autoimmune diseases, current evidence does not advocate for routine screening unless the patient's clinical history suggests their presence.<xref ref-type="bibr" rid="article-17385.r4">[4]</xref></p>
      </sec>
      <sec id="article-17385.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Approximately 50% of patients will experience natural hair regrowth within 1 year without intervention, and some may decide not to seek treatment. For those who choose treatment, intralesional and topical corticosteroids are often the initial therapy for patchy alopecia areata.</p>
        <p>
<bold>Intralesional Corticosteroids</bold>
</p>
        <p>Triamcinolone acetonide, at concentrations ranging from 5 to 10 mg/mL and administered every 4 to 6 weeks on the scalp, stimulates localized regrowth in 60% to 67% of patients.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref>&#x000a0;Clinicians typically use triamcinolone acetonide concentrations of 2.5 to 5 mg/mL to treat the eyebrows and beard in patients, and they&#x000a0;can expect new hair growth within 6 to 8 weeks. Clinicians repeat injections until complete hair regrowth is achieved, while therapy discontinuation is recommended if no improvement is observed within 6 months. A comparative study among intralesional triamcinolone acetonide concentrations of 2.5 mg/mL, 5 mg/mL, and 10 mg/mL reveals similar hair regrowth rates irrespective of the concentration. However, the risk of cutaneous atrophy is more significant with the higher concentrations of 10 mg/mL triamcinolone.<xref ref-type="bibr" rid="article-17385.r15">[15]</xref>&#x000a0;</p>
        <p>Patients typically receive approximately 0.1 mL of triamcinolone acetonide spaced 1 cm apart in the affected area. The dose of triamcinolone acetonide usually ranges around 20 mg per session on the scalp but should not exceed 40 mg to mitigate systemic adverse effects. Topical application of prilocaine or lidocaine cream 30 to 60 minutes before injections may be beneficial for patients seeking pain reduction.&#x000a0;</p>
        <p>Although intralesional betamethasone is a consideration for treatment, further studies are necessary to assess its efficacy.<xref ref-type="bibr" rid="article-17385.r16">[16]</xref>&#x000a0;Potential adverse effects of corticosteroids include localized skin atrophy, pain, telangiectasia, and depigmentation. Systemic adverse effects such as adrenal suppression or Cushing syndrome are rare. However, the use of intralesional corticosteroids on the face may lead to significant hypopigmentation in individuals with darkly pigmented skin.&#x000a0;</p>
        <p>
<bold>Topical Corticosteroids</bold>
</p>
        <p>Betamethasone dipropionate 0.05% cream, lotion, or ointment is a potent topical glucocorticoid used to treat alopecia areata. Healthcare professionals typically reserve topical corticosteroids for children and patients who cannot tolerate numerous injections. Patients apply betamethasone to the affected area daily, extending 1 cm beyond the affected border. Clinicians discontinue topical corticosteroids if symptoms do not improve within 3 months. However, in cases where progress is noticeable, patients continue using betamethasone while gradually reducing the dosage. Betamethasone is applied without occlusion to reduce the risk of adverse effects. Using it under occlusion may increase the risk of potential adverse effects, which align with those associated with intralesional injections.</p>
        <p>
<bold>Immunotherapy and JAK Inhibitors</bold>
</p>
        <p>Patients with extensive disease, often characterized by more than 50% hair loss on the scalp, may explore treatment alternatives such as topical immunotherapy or oral JAK inhibitors to reduce the necessity of numerous injections associated with intralesional corticosteroids. Moreover, a retrospective study revealed the superior efficacy of topical immunotherapy compared to intralesional corticosteroids in patients with hair loss patches exceeding 50 cm&#x000b2;.<xref ref-type="bibr" rid="article-17385.r17">[17]</xref></p>
        <p>The choice between topical immunotherapy and JAK inhibitors depends on patient preference and availability. JAK inhibitors are easier to apply but carry the risk of systemic adverse effects. On the other hand, topical immunotherapy requires careful application and may induce discomfort and cutaneous adverse effects.</p>
        <p>A potent contact allergen, such as diphenylcyclopropenone (DPCP) or squaric acid dibutyl ester (SADBE), can be applied weekly to the scalp to stimulate hair regrowth. Clinicians obtain both these allergens from compounding pharmacies. Treatment begins by applying a small patch at full concentration to sensitize the patient. After 1 to 2 weeks, complete treatment begins with diluted solution concentrations, gradually increasing the concentration weekly. The dose that causes mild dermatitis is the dose used for future doses. Patients may titrate up to a maximum dose of 2%.</p>
        <p>Following treatment initiation, clinicians typically assess hair growth approximately 3 months later. A recent meta-analysis examining clinical outcomes of contact immunotherapy for alopecia areata indicates that 74.6% of patients with patchy alopecia experience hair regrowth, compared to 54.4% of patients with alopecia totalis and alopecia universalis. Among patients who receive maintenance treatment, the recurrence rate is 38.2%, contrasting with 49% among those who do not receive maintenance treatment.<xref ref-type="bibr" rid="article-17385.r18">[18]</xref></p>
        <p>Oral baricitinib, a selective and reversible JAK1 and JAK2 inhibitor, treats alopecia areata by suppressing the activation of T lymphocytes. Patients typically require ongoing therapy to sustain the benefits achieved. The United States Food and Drug Administration (FDA) has issued a boxed warning for JAK inhibitors, cautioning about the risk of severe infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis. Initial dosing is 2 mg/d with an increase to 4 mg/d if the response is inadequate after 3 months. Patients with severe symptoms may start at the 4 mg/d dose. Upon achieving an adequate response, clinicians reduce the dose to 2 mg. Therapy is discontinued if no improvement is observed after 6 months.&#x000a0;</p>
        <p>Oral ritlecitinib, an inhibitor of JAK3 and the tyrosine kinase expressed in the hepatocellular carcinoma kinase family, is approved by the&#x000a0;FDA for patients aged 12 and older with alopecia areata. Similar to baricitinib, continued use is likely necessary to maintain the effects. The initial dose is 50 mg/d. Potential adverse effects are increased risk for severe infection, death, malignancy, lymphoproliferative disorders, major adverse cardiovascular events, thromboembolic events, and hematologic, hepatic, and creatine phosphokinase laboratory abnormalities.</p>
        <p>
<bold>Additional Therapies</bold>
</p>
        <p>Various additional therapies are available for patients with refractory disease or who cannot receive first-line therapies, including topical or oral minoxidil, methotrexate, azathioprine, cyclosporine, platelet-rich plasma, topical anthralin, excimer laser, and ultraviolet A photochemotherapy (PUVA).<xref ref-type="bibr" rid="article-17385.r19">[19]</xref><xref ref-type="bibr" rid="article-17385.r20">[20]</xref><xref ref-type="bibr" rid="article-17385.r21">[21]</xref><xref ref-type="bibr" rid="article-17385.r22">[22]</xref><xref ref-type="bibr" rid="article-17385.r23">[23]</xref><xref ref-type="bibr" rid="article-17385.r24">[24]</xref><xref ref-type="bibr" rid="article-17385.r25">[25]</xref></p>
        <p>Systemic glucocorticoids may promote hair growth, but their adverse effects limit their use. However, patients experiencing rapid and extensive hair loss may find oral glucocorticoids beneficial. Furthermore, relapse occurs within 1 year in approximately one-third of responsive patients, with the likelihood of relapses increasing over time.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref><xref ref-type="bibr" rid="article-17385.r25">[25]</xref>&#x000a0;Ongoing investigational treatments include recombinant IL-2, hydroxychloroquine, and simvastatin with ezetimibe.<xref ref-type="bibr" rid="article-17385.r21">[21]</xref><xref ref-type="bibr" rid="article-17385.r22">[22]</xref><xref ref-type="bibr" rid="article-17385.r23">[23]</xref><xref ref-type="bibr" rid="article-17385.r24">[24]</xref><xref ref-type="bibr" rid="article-17385.r25">[25]</xref></p>
        <p>Currently, effective topical therapies for eyelashes are lacking. However, some individuals may observe improvement with systemic therapy. Patients may explore the option of using false eyelashes. Other cosmetic alternatives include tattooed eyebrows, wigs, hairpieces, and head shaving.</p>
        <p>Alopecia areata can be distressing and may result in anxiety and depression for some individuals. Consulting with a psychologist or psychiatric provider may be necessary in such cases.&#x000a0;</p>
      </sec>
      <sec id="article-17385.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Specific medical conditions that may be mistaken for alopecia areata include androgenetic alopecia, traction alopecia, trichotillomania, tinea capitis, secondary syphilis, aplasia cutis, and temporal triangular alopecia.</p>
      </sec>
      <sec id="article-17385.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Individuals with alopecia areata maintain the potential for hair regrowth, as 34% to 50% of those with patchy hair loss experience spontaneous recovery within 1 year. However, most patients will encounter recurrence, and less than 10% will recover completely.<xref ref-type="bibr" rid="article-17385.r1">[1]</xref>&#x000a0;Approximately 10% of patients with patchy disease will develop alopecia totalis or alopecia universalis.&#x000a0;</p>
        <p>Prognostic factors, including the extent of hair loss and age at diagnosis, play a crucial role. A diagnosis in childhood and an ophiasis distribution suggest an unfavorable prognosis.<xref ref-type="bibr" rid="article-17385.r4">[4]</xref> Furthermore, a family history of alopecia areata, severe disease, duration of more than 1 year, nail dystrophy, atopy, or concurrent autoimmune disease may indicate a poor prognosis.<xref ref-type="bibr" rid="article-17385.r3">[3]</xref><xref ref-type="bibr" rid="article-17385.r26">[26]</xref><xref ref-type="bibr" rid="article-17385.r27">[27]</xref></p>
      </sec>
      <sec id="article-17385.s12" sec-type="Complications">
        <title>Complications</title>
        <p>&#x000a0;Some potential complications of alopecia areata include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Depression and anxiety, permanent hair loss, recurrence, nail abnormalities, sunburn, and skin damage.</p>
          </list-item>
          <list-item>
            <p>Unpredictable pattern, texture, and rate of hair regrowth.</p>
          </list-item>
          <list-item>
            <p>Increased risk of concurrent dermatologic and systemic illnesses such as thyroid disease, vitiligo, psoriasis,&#x000a0;lupus erythematosus, and atopic dermatitis.<xref ref-type="bibr" rid="article-17385.r28">[28]</xref><xref ref-type="bibr" rid="article-17385.r29">[29]</xref></p>
          </list-item>
          <list-item>
            <p>Skin atrophy, hypopigmentation, infections, malignancy, dermatitis, and thrombosis due to adverse effects of medication.</p>
          </list-item>
          <list-item>
            <p>A 3-fold higher risk of developing retinal diseases such as retinal detachment, retinal vascular occlusion, and retinopathy.<xref ref-type="bibr" rid="article-17385.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17385.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Alopecia areata is an autoimmune condition characterized by sudden and patchy hair loss, which can occur on any part of the body. This condition arises from a malfunction in the body's natural defense mechanisms. Patients should find encouragement in knowing that the hair follicles are not permanently damaged, suggesting that regrowth is possible, and nearly half of affected individuals experience spontaneous hair regrowth within 1 year.&#x000a0;</p>
        <p>Although alopecia areata is not a life-threatening condition, its psychosocial impact can be significant. Seeking emotional support from a psychologist, psychiatric provider, or support group can be beneficial. In addition, resources are available through the National Alopecia Areata Foundation's website at&#x000a0;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.naaf.org/">https://www.naaf.org/</ext-link>.</p>
        <p>Currently, alopecia areata lacks a permanent cure, and many individuals with this condition will experience recurring episodes of hair loss throughout their lives. However, not all affected individuals require or desire treatment. For those who do, multiple treatment options are available.</p>
        <p>Cosmetic choices may help manage the appearance of hair loss:</p>
        <list list-type="bullet">
          <list-item>
            <p>High-quality wigs and hairpieces offer a natural appearance and boost confidence.</p>
          </list-item>
          <list-item>
            <p>False eyelashes can enhance the eye area for individuals experiencing eyelash involvement.</p>
          </list-item>
          <list-item>
            <p>Tattooed eyebrows offer a permanent solution for addressing eyebrow hair loss.</p>
          </list-item>
        </list>
        <p>Various medications are available for managing alopecia areata, some of which are listed below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Topical or injected corticosteroids reduce inflammation and promote hair regrowth.</p>
          </list-item>
          <list-item>
            <p>Topical immunotherapy stimulates the immune system to facilitate hair growth.</p>
          </list-item>
          <list-item>
            <p>Anthralin application in the affected areas can promote hair regrowth.</p>
          </list-item>
          <list-item>
            <p>Minoxidil, whether taken orally or applied topically, may occasionally aid hair regrowth.</p>
          </list-item>
          <list-item>
            <p>Oral JAK inhibitors are a newer treatment option prescribed for more severe cases of alopecia areata.</p>
          </list-item>
        </list>
        <p>Alopecia areata is commonly associated with other dermatologic and systemic diseases. Patients must be educated on the symptoms of thyroid disease, systemic lupus erythematosus, psoriasis, and atopic dermatitis and report any symptoms they experience. Healthcare professionals treating patients with Down syndrome and polyglandular autoimmune syndrome type 1 should be vigilant due to the heightened risk of alopecia areata and should monitor for any signs of patchy hair loss.</p>
      </sec>
      <sec id="article-17385.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Comprehensive care for patients with alopecia areata involves addressing both the psychosocial and physical aspects, along with monitoring for associated illnesses. Various healthcare specialties, including primary care, dermatology, rheumatology, and endocrinology, frequently encounter patients with alopecia areata. To effectively care for these individuals, healthcare professionals must possess essential knowledge for diagnosis and management, understand potential treatment adverse effects, and recognize the psychosocial impact of alopecia areata. In addition, clinicians must remain vigilant for associated dermatologic and systemic illnesses, ensuring seamless interprofessional communication of specialty opinions and relevant test results.</p>
        <p>A strategic treatment plan is crucial to optimize outcomes and minimize adverse effects. Clinicians play a vital role in helping patients understand that hair regrowth may not occur rapidly, providing both medical and psychosocial support. Establishing realistic expectations through shared decision-making between patients and clinicians is crucial in determining whether to pursue treatment. Involving a psychologist or psychiatric healthcare professional can play a crucial role in alleviating symptoms of depression and anxiety among individuals with alopecia areata.<xref ref-type="bibr" rid="article-17385.r30">[30]</xref></p>
        <p>Providing resources for additional information and community support can help mitigate feelings of isolation. By endorsing an interprofessional team centered around skill, communication, strategy, and responsibility, healthcare professionals can deliver optimal patient-centered care to those affected by alopecia areata. Enhancing the comprehensive knowledge of healthcare professionals, including understanding the pathophysiology, clinical manifestations, and treatment strategies, while improving skills in patient communication, expectations, and emotional support, will elevate clinicians' capacity to deliver optimal care for patients with alopecia areata.</p>
      </sec>
      <sec id="article-17385.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17385&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17385">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/alopecia-areata/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17385">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17385/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17385">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17385.s16">
        <fig id="article-17385.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Alopecia Areata. Alopecia areata presents as localized patches of hair loss on the scalp, which develop over a few weeks. Contributed by S Verma, MBBS, DVD, FRCP, FAAD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Alopecia__areata__SV1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17385.s17">
        <fig id="article-17385.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Alopecia Areata Dystrophic Nails. The image shows dystrophic nails characterized by fine nail pitting, trachyonychia, onychorrhexis, red spotting on the lunulae, onycholysis, and onychomadesis. Contributed by R Rapini, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Alopecia__areata__nails__RR__scan__2-13-81" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17385.s18">
        <fig id="article-17385.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Alopecia Areata Hair Loss. The classic presentation of alopecia areata involves isolated, smooth, sudden, nonscarring, and patchy hair loss on the scalp or any area with hair growth. Contributed by H Ali Syed, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="AA" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-17385.s19">
        <fig id="article-17385.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Alopecia Areata Biopsy. Lymphocytes are clustered around the hair papilla at the base of the hair follicle, often called a "swarm of bees," which are observed in the early or active stages of the condition. Contributed by R Rapini, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Alopecia__areata__swarm__of__bees-07-2393" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17385.s20">
        <title>References</title>
        <ref id="article-17385.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Etzioni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paus</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Alopecia areata.</article-title>
            <source>N Engl J Med</source>
            <year>2012</year>
            <month>Apr</month>
            <day>19</day>
            <volume>366</volume>
            <issue>16</issue>
            <fpage>1515</fpage>
            <page-range>1515-25</page-range>
            <pub-id pub-id-type="pmid">22512484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>403</fpage>
            <page-range>403-423</page-range>
            <pub-id pub-id-type="pmid">34403083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safavi</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Suman</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Moshell</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989.</article-title>
            <source>Mayo Clin Proc</source>
            <year>1995</year>
            <month>Jul</month>
            <volume>70</volume>
            <issue>7</issue>
            <fpage>628</fpage>
            <page-range>628-33</page-range>
            <pub-id pub-id-type="pmid">7791384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratt</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Messenger</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Christiano</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Sundberg</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Alopecia areata.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2017</year>
            <month>Mar</month>
            <day>16</day>
            <volume>3</volume>
            <fpage>17011</fpage>
            <pub-id pub-id-type="pmid">28300084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirzoyev</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Schrum</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MDP</given-names>
              </name>
              <name>
                <surname>Torgerson</surname>
                <given-names>RR</given-names>
              </name>
            </person-group>
            <article-title>Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009.</article-title>
            <source>J Invest Dermatol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>134</volume>
            <issue>4</issue>
            <fpage>1141</fpage>
            <page-range>1141-1142</page-range>
            <pub-id pub-id-type="pmid">24202232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barahmani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schabath</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Duvic</surname>
                <given-names>M</given-names>
              </name>
              <collab>National Alopecia Areata Registry</collab>
            </person-group>
            <article-title>History of atopy or autoimmunity increases risk of alopecia areata.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>61</volume>
            <issue>4</issue>
            <fpage>581</fpage>
            <page-range>581-91</page-range>
            <pub-id pub-id-type="pmid">19608295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daneshpazhooh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nazemi</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bigdeloo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yoosefi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mucocutaneous findings in 100 children with Down syndrome.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2007</year>
            <season>May-Jun</season>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-20</page-range>
            <pub-id pub-id-type="pmid">17542890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schepis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Siragusa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pettinato</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Romano</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>An updated survey on skin conditions in Down syndrome.</article-title>
            <source>Dermatology</source>
            <year>2002</year>
            <volume>205</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-8</page-range>
            <pub-id pub-id-type="pmid">12399669</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Dominguez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ilmarinen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Costigan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Irvine</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome.</article-title>
            <source>Br J Dermatol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>154</volume>
            <issue>6</issue>
            <fpage>1088</fpage>
            <page-range>1088-93</page-range>
            <pub-id pub-id-type="pmid">16704638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajabi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Senna</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Rezaei</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Alopecia areata: a review of disease pathogenesis.</article-title>
            <source>Br J Dermatol</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>179</volume>
            <issue>5</issue>
            <fpage>1033</fpage>
            <page-range>1033-1048</page-range>
            <pub-id pub-id-type="pmid">29791718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ting</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Association between alopecia areata and retinal diseases: A nationwide population-based cohort study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>87</volume>
            <issue>4</issue>
            <fpage>771</fpage>
            <page-range>771-778</page-range>
            <pub-id pub-id-type="pmid">34794815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fern&#x000e1;ndez-Domper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ballesteros-Redondo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Va&#x000f1;&#x000f3;-Galv&#x000e1;n</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Trichoscopy: An Update.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>114</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-333</page-range>
            <pub-id pub-id-type="pmid">36574917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bains</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The Role of Dermoscopy in Severity Assessment of Alopecia Areata: A Tertiary Care Center Study.</article-title>
            <source>J Clin Aesthet Dermatol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>45</fpage>
            <page-range>45-50</page-range>
            <pub-id pub-id-type="pmid">33144912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f3;mez-Quispe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz Moreno-Arrones</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hermosa-Gelbard</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Va&#x000f1;&#x000f3;-Galv&#x000e1;n</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saceda-Corralo</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Trichoscopy in Alopecia Areata.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>114</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">36067826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>AlJasser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alharbi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abahussein</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>McElwee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Benefit of different concentrations of intralesional triamcinolone acetonide in alopecia areata: An intrasubject pilot study.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>338</fpage>
            <page-range>338-40</page-range>
            <pub-id pub-id-type="pmid">26183987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melo</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Dutra</surname>
                <given-names>TBS</given-names>
              </name>
              <name>
                <surname>Baggieri</surname>
                <given-names>VMAC</given-names>
              </name>
              <name>
                <surname>Tortelly</surname>
                <given-names>VD</given-names>
              </name>
            </person-group>
            <article-title>Intralesional betamethasone as a therapeutic option for alopecia areata.</article-title>
            <source>An Bras Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-312</page-range>
            <pub-id pub-id-type="pmid">29723356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ro</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Alopecia areata in Korea (1982-1994).</article-title>
            <source>J Dermatol</source>
            <year>1995</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>858</fpage>
            <page-range>858-64</page-range>
            <pub-id pub-id-type="pmid">8557859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>154</volume>
            <issue>10</issue>
            <fpage>1145</fpage>
            <page-range>1145-1151</page-range>
            <pub-id pub-id-type="pmid">30073292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Michelle</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Juhasz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muller Ramos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Atanaskova Mesinkovska</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review.</article-title>
            <source>Int J Dermatol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>1013</fpage>
            <page-range>1013-1019</page-range>
            <pub-id pub-id-type="pmid">32516434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoehr</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Colavincenzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vanderweil</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Off-Label Use of Topical Minoxidil in Alopecia: A Review.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>237</fpage>
            <page-range>237-250</page-range>
            <pub-id pub-id-type="pmid">30604379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strazzulla</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Avila</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lo Sicco</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>An Overview of the Biology of Platelet-Rich Plasma and Microneedling as Potential Treatments for Alopecia Areata.</article-title>
            <source>J Investig Dermatol Symp Proc</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>S21</fpage>
            <page-range>S21-S24</page-range>
            <pub-id pub-id-type="pmid">29273100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cervantes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jimenez</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>DelCanto</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Alopecia Areata with Simvastatin/Ezetimibe.</article-title>
            <source>J Investig Dermatol Symp Proc</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>S25</fpage>
            <page-range>S25-S31</page-range>
            <pub-id pub-id-type="pmid">29273101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iorizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tosti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Emerging drugs for alopecia areata: JAK inhibitors.</article-title>
            <source>Expert Opin Emerg Drugs</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-81</page-range>
            <pub-id pub-id-type="pmid">29466675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aldahan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fayne</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Emerson</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Nouri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of fractional lasers in treating alopecia: a literature review.</article-title>
            <source>Lasers Med Sci</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>1919</fpage>
            <page-range>1919-1925</page-range>
            <pub-id pub-id-type="pmid">28812164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Putterman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Castelo-Soccio</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>78</volume>
            <issue>6</issue>
            <fpage>1207</fpage>
            <page-range>1207-1209.e1</page-range>
            <pub-id pub-id-type="pmid">29754888</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Alopecia areata update.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>549</fpage>
            <page-range>549-66; quiz 567-70</page-range>
            <pub-id pub-id-type="pmid">10727299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>You</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Factors Associated with Severity of Alopecia Areata.</article-title>
            <source>Ann Dermatol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-570</page-range>
            <pub-id pub-id-type="pmid">28966512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Comorbidities in alopecia areata: A systematic review and meta-analysis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>80</volume>
            <issue>2</issue>
            <fpage>466</fpage>
            <page-range>466-477.e16</page-range>
            <pub-id pub-id-type="pmid">30031145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyritsi</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kanaka-Gantenbein</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Thyroid Disease in Specific Genetic Syndromes in Childhood and Adolescence.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>543</fpage>
            <pub-id pub-id-type="pmid">32973676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17385.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mulinari-Brenner</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Psychosomatic aspects of alopecia areata.</article-title>
            <source>Clin Dermatol</source>
            <year>2018</year>
            <season>Nov-Dec</season>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>709</fpage>
            <page-range>709-713</page-range>
            <pub-id pub-id-type="pmid">30446192</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
